Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?

Oral pharmacotherapy constitutes second-line treatment for overactive bladder (OAB) after lifestyle modifications, bladder retraining, and pelvic floor muscle exercises. Antimuscarinics have an established role in the treatment of OAB. However, antimuscarinics are known to have low persistence rates...

Full description

Bibliographic Details
Main Authors:	Ömer Acar, Mustafa Levent Erton, Tufan Tarcan
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2019-06-01
Series:	Journal of Urological Surgery
Subjects:	Overactive bladder Pharmacotherapy Antimuscarinic Beta3 agonist Side effects
Online Access:	http://jurolsurgery.org/archives/archive-detail/article-preview/nsights-into-the-management-of-overactive-bladder-/27467

Similar Items

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
by: Yuh-Chen Kuo, et al.
Published: (2023-01-01)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
by: Luisa Gracio Ferreira Sartori, et al.
Published: (2023-08-01)

Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome
by: Megha O. Raj, et al.
Published: (2024-08-01)

Perspectives on mirabegron in the treatment of overactive bladder syndrome: A new beta-3 adrenoceptor agonist
by: Chia-Hao Kuei, et al.
Published: (2015-03-01)

A historical perspective on anticholinergics in overactive bladder (OAB) treatment: “Foundations, current practices, and future prospects”
by: D. Carolina Ochoa, et al.
Published: (2024-12-01)

Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials
by: Hann-Chorng Kuo, et al.
Published: (2015-03-01)

Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms
by: Chen-Hsun Ho, et al.
Published: (2010-10-01)

Comparative persistence, switch rates, and predictors for discontinuation of antimuscarinics for overactive bladder: A 10-year nationwide population-based study in Taiwan
by: Hao-Wei Chen, et al.
Published: (2018-01-01)

THE EFFICACY COMPARISON OF MIRABEGRON AS A MONOTHERAPY VERSUS ITS COMBINATION WITH SOLIFENACIN IN OVERACTIVE BLADDER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
by: Hasan Madani, et al.
Published: (2021-07-01)

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain
by: Peral C, et al.
Published: (2016-09-01)

Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022-09-01)

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
by: Michael Kennelly, et al.
Published: (2022-10-01)

Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
by: Vozmediano-Chicharro R, et al.
Published: (2020-08-01)

Mirabegron, a breakthrough in overactive bladder syndrome?
by: Almudena Maestro Nombela, et al.
Published: (2017-05-01)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
by: Löfling L, et al.
Published: (2019-01-01)

The effectiveness of intravesical oxybutynin in the management of overactive bladder: a clinical study
by: Shoeb Alahmad, et al.
Published: (2024-12-01)

An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder
by: Zhipeng Zhang, et al.
Published: (2025-01-01)

Mirabegron for Overactive Bladder: A Novel, First-in-Class β3- Agonist Therapy
by: Mohammed Imran, et al.
Published: (2013-09-01)

Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives
by: Robinson D, et al.
Published: (2023-05-01)

Does Mirabegron the β3 Agonist Frequently Used in the Treatment of Overactive Bladder Really Affect the Respiratory System Negatively ? A Prospective Study
by: Şenol Adanur, et al.
Published: (2024-12-01)

Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study
by: Sheng-Fu Chen, et al.
Published: (2022-10-01)

Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare–Medicaid Populations in a Historic Database
by: Jonathan H. Watanabe, et al.
Published: (2023-09-01)

Bladder contractility index changes with short-term antimuscarinic therapy in patients with detrusor overactivity: A placebo controlled randomised study
by: Alka Ashok Bhide, et al.
Published: (2023-12-01)

The sensory system is a target for pharmaceutical therapy of overactive bladder
by: Christopher R. Chapple
Published: (2024-09-01)

Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder
by: Jee Soo Park, et al.
Published: (2025-01-01)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
by: Hidenori Ito, et al.
Published: (2022-06-01)

Overactive bladder – 18 years – Part II
by: Jose Carlos Truzzi, et al.
Published: (2016-04-01)

Constitution and Validation of a New Symptom Assessment Tool for Overactive Bladder: Marmara Overactive Bladder Questionnaire (M-OBQ)
by: Tufan Tarcan, et al.
Published: (2014-11-01)

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists
by: Mateusz Małkowski, et al.
Published: (2024-01-01)

MODERN POSSIBILITIES OF MEDICAL TREATMENT OF OVERACTIVE BLADDER IN WOMEN
by: I. A. Apolikhina, et al.
Published: (2017-12-01)

Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis
by: Peng Liu, et al.
Published: (2022-10-01)

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder
by: Roger R. Dmochowski, et al.
Published: (2023-04-01)

Unraveling the impact of Lactobacillus spp. and other urinary microorganisms on the efficacy of mirabegron in female patients with overactive bladder
by: Zhipeng Zhou, et al.
Published: (2022-11-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder
by: Yan Hu, et al.
Published: (2024-04-01)

Differences in bladder neck angles between female patients with overactive bladders and healthy peers
by: Mehmet Yoldas, et al.
Published: (2024-06-01)

Botulinum toxin A for the Treatment of Overactive Bladder
by: Po-Fan Hsieh, et al.
Published: (2016-02-01)

Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment
by: İrfan Şafak Barlas, et al.
Published: (2024-04-01)

ONABOTULINUM TOXIN-A FOR OVERACTIVE BLADDER
by: Mahmood Shakir Abdulkarim
Published: (2016-12-01)

The Urobiome and Its Role in Overactive Bladder
by: Sangrak Bae, et al.
Published: (2022-09-01)